Entities / Company
Spero Therapeutics (United States).
company in Cambridge, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 15
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Spero Therapeutics' ownership structure was reported, showing retail investors hold 54%, institutions 20%, and hedge funds 6.8%.Speculative1 report
-
RSI reading of 27.97 suggests selling pressure is exhausting, coinciding with analysts agreeing on better earnings for Spero Therapeutics.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Spero Therapeutics (United States) this week
News at the entities that move Spero Therapeutics (United States) most-
GSK StructuralThe FDA approved GSK's Jemperli drug, while Memorial Sloan Kettering Cancer Center was involved in the AZUR-1 trial.Moves Spero Therapeutics (United States)
-
FDA StructuralLitigation regarding FDA approval process.Moves Spero Therapeutics (United States)
-
Cambridge Shared contextCambridge is attracting talent and innovation, with AI and tech companies driving demand for office space.Moves Spero Therapeutics (United States)
Connections
The 3 strongest of 15, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
GSK Structural
GSK acts as the development partner and rights holder for Spero Therapeutics, providing milestone payments and receiving collaboration revenue.
-
FDA Structural
Spero Therapeutics relies on the FDA for regulatory approval and review of its clinical data and studies.
-
Cambridge Shared context
Spero Therapeutics is headquartered and operates within Cambridge, Massachusetts.
History
Events by the month they beganJune 2026
3 events- Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.
- Spero Therapeutics' ownership structure was reported, showing retail investors hold 54%, institutions 20%, and hedge funds 6.8%.
- RSI reading of 27.97 suggests selling pressure is exhausting, coinciding with analysts agreeing on better earnings for Spero Therapeutics.